Summary An immunohistochemical study of the expression of epidermal growth factor receptor (EGFR) and c-erbB-2 protein was performed in fresh-frozen sections from 30 patients with transitional cell cancers (TCCs) of the upper urinary tract (15 renal pelvic cancers, 15 ureteral cancers) who underwent total nephroureterectomy. We followed them and examined whether TCC appeared in the urinary bladder. The follow-up period ranged from 116 to 2348 days (mean 666 days). (Mori et al., 1989). Therefore, this protein has been assumed to be a growth factor receptor that plays a role in mitogenic signalling in the fetal epithelium. The overexpression of c-erbB-2 has been shown to be correlated with lymph node metastasis and a poorer prognosis in those with breast cancer, suggesting that c-erbB-2 may play an important role in the progression of cancers (Slamon et al., 1987; Walker et al.. 1989 ).
Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein which has tyrosine kinase activity and augments cell proliferation on interaction with its ligand, EGF. EGFR is expressed at increased levels in certain carcinomas, such as breast cancer (Sainsbury et al.. 1987; Harris et al.. 1989) , oesophageal cancer (Ozawa et al., 1989) and urinary bladder cancer (Neal et al., 1985 (Neal et al., . 1990 ; Lipponen and Eskelinen. 1994) . In those carcinomas, the expression of the EGFR appears to be associated with the patient's prognosis. The c-erbB-2 gene encodes a transmembrane glycoprotein which is supposed to have similar function to EGFR (Yamamoto et al.. 1986 : Lee et al.. 1989 . Immunohistological studies have revealed that the c-erbB-2 protein is commonly located in fetal epithelial cells but is barely detectable in post-natal tissues (Mori et al., 1989) . Therefore, this protein has been assumed to be a growth factor receptor that plays a role in mitogenic signalling in the fetal epithelium. The overexpression of c-erbB-2 has been shown to be correlated with lymph node metastasis and a poorer prognosis in those with breast cancer, suggesting that c-erbB-2 may play an important role in the progression of cancers (Slamon et al., 1987; Walker et al.. 1989) .
Transitional cell cancers (TCCs) in the urinary tract appear to occur multicentrically. After a total nephroureterectomy for TCCs of the renal pelvis or ureter, patients require continued surveillance, because the incidence of a subsequent bladder cancer is about 20-40% (Batara and Grabsteld, 1976; Kakizoe et al., 1980; Nielsen and Ostri, 1988; Catalona, 1992) . Although several studies have been performed to determine the relationship between urothelial cancers of the upper urinary tract and secondary urinary bladder cancers after total nephroureterectomy, none of the criteria examined was found to be predictive of recurrence in urinary bladder. We reported that EGFR and c-erbB-2 were also overexpressed in TCCs in ureter or renal pelvis, and that the degree of expression was correlated with the histopathological grade of the tumour and the degree of invasion (Kimura et al., 1992 Immunoperoxidase staining Frozen sections were cut at 5 ytm, air dried for 30 min and fixed in cold acetone for 10 min. One section from each sample was subjected to immunohistochemical staining for EGFR and c-erbB-2 and to examination of histopathology. The immunohistochemical study was performed using the streptavidin-biotin bridge technique as described elsewhere (Tomita et al., 1990 EGFR. epidermal grow-th factor receptor. *P <(0.05 (x = 4.887.
Yates' correction). (Neal et al., 1985 (Neal et al., , 1990 Moriyama et al., 1991; Kimura et al., 1992; Lipponen and Eskelinen, 1994 
